12:00 AM
Jun 11, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ponatinib: Additional Phase II data

Updated data from 444 evaluable patients in the single-arm, international, pivotal Phase II PACE trial showed that once-daily 45 mg oral ponatinib produced an MCyR rate of 54% in patients with chronic phase CML (n=267), with 44% of patients achieving a complete cytogenetic response (CCyR) and 37% achieving a major molecular response (MMR). Median follow-up was 10.1 months. MMR is the primary endpoint in Ariad's Phase III trial evaluating ponatinib vs. imatinib that is slated to begin next quarter.

In patients who previously received only 1 tyrosine kinase inhibitor (n=21), 86% achieved an MCyR....

Read the full 465 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >